309734-26-7

Upstream product

• 53518-15-3 Coumarin 151 
• 90-02-8 salicylaldehyde 

Downstream Products

• 53518-15-3 Coumarin 151 

Relevant academic research and scientific papers

Novel coumarin rhenium(I) and -(V) complexes: Formation, DFT and DNA binding studies

Herein, we report the formation and characterisation of novel rhenium(I) and -(V) compounds with coumarin bidentate chelates: trans-[ReOBr2(PPh3)(hbc)] (1) (Hhbc = 7-(2-hydroxybenzylideneamino)-4-(trifluoromethyl)-2H-chromen-2-one), fac-[Re(CO)3Cl(aomc)] (2) (aomc = 7-(((2-amino-4-oxo-4H-chromen-3-yl)methylene)amino)-4-(trifluoromethyl)-2H-chromen-2-one) and fac-[Re(CO)3Cl(moac)] (3) (moac = 7-(((2-methoxy-4-oxochroman-3-yl)methylene)amino)-4-(trifluoromethyl)-2H-chromen-2-one). The coumarin free-ligands and the metal complexes 1–3 were characterized by NMR, UV–Vis and FTIR spectroscopy, melting point and molar conductivity measurements as well as time-of-flight mass spectrometry. Their structural elucidations were supported by the respective solid state structures of 1, Hhbc and moac. DNA binding studies conducted using the facial tricarbonylrhenium(I) complexes 2 and 3, revealed that they are DNA groove binders with intrinsic binding constants in the order of 105 and 104 M bp, respectively. This study was also complemented using density functional theory (DFT) and time-dependent DFT methods to attain a deeper understanding into the structural parameters, infrared and electronic spectra of these coumarin free-ligands and their metal complexes 1–3.

Coumarin-modified fluorescent cyclic iridium (III) complex as well as preparation method and application thereof

The invention discloses a coumarin-modified fluorescent type cyclic iridium (III) complex as well as a preparation method and application thereof. The structural formula of the coumarin derivative isshown as a formula (I), wherein the R1 is hydrogen and formyl, and R2 is 7-amino-4-methylcoumarin, 7-amino-4-trifluoromethylcoumarin and 6-aminocoumarin. The growth inhibition ratio experiment of thetarget complex on human alveolar basal epithelial tumor cells (A549) is tested. The results shows that compared with salicylaldehyde-coumarin Schiff base ligands, basic metal iridium dimers and cis-platinum drugs, the target complex shows good anti-tumor activity. The introduction of coumarin groups and the special structure of the complex provides the compound with good fluorescence characteristics.

Fluorescent iridium(iii) coumarin-salicylaldehyde Schiff base compounds as lysosome-targeted antitumor agents

Six fluorescent half-sandwich iridium(iii) coumarin-salicylaldehyde Schiff base (O^N) compounds ([(?5-Cp*)Ir(O^N)Cl]) were prepared and characterized. The introduction of a coumarin unit increased the antitumor activity (IC50: 9.9 ± 0.1 μM-40.7 ± 12.9 μM) of these compounds, the best of which was nearly two times that of clinical cisplatin. The results of laser confocal microscopy demonstrated that these compounds possessed an energy-dependent cellular uptake mechanism, accumulated in the lysosomes (Pearson co-localization coefficient: ~0.7), damaged the integrity of the lysosomes, and induced apoptosis. The compounds could also decrease the mitochondrial membrane potential, catalyze the oxidation of the coenzyme (nicotinamide-adenine dinucleotide) and improve the levels of the intracellular reactive oxygen species, following an antitumor mechanism of oxidation. Additionally, these compounds could block the metastasis of tumor cells. Above all, these iridium(iii) compounds show potential as antitumor agents with dual functions: lysosomal damage and anti-metastasis.

Fluorescence turn-on sensors for HSO4-

A coumarin-based derivative (1), a highly selective and sensitive turn-on fluorogenic probe for the detection of HSO4- ions in aqueous solution, has been designed and synthesized. Various spectroscopic and DFT calculations revealed t